Combined gemcitabine and carboplatin therapy for carcinomas in dogs

Journal of Veterinary Internal Medicine

Volumn 23, Issue 1, 2009, Pages 130-137

  Dominguez, P A ^a   Dervisis, N G ^a   Cadile, C D ^a   Sarbu, L ^a   Kitchell, B E ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Antimetabolite; Canine; Chemotherapy; Platinum agent; Synergism

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; DEOXYCYTIDINE; DRUG DERIVATIVE; GEMCITABINE;

ANIMAL; ANIMAL DISEASE; ARTICLE; CARCINOMA; CLINICAL TRIAL; DOG; DOG DISEASE; DRUG COMBINATION; FEMALE; MALE;

ANIMALS; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CARCINOMA; DEOXYCYTIDINE; DOG DISEASES; DOGS; DRUG THERAPY, COMBINATION; FEMALE; MALE;

ANIMALIA; CANIS FAMILIARIS;

EID: 61349146549     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1939-1676.2008.0248.x     Document Type: Article

References (42)

1. Plunkett W, Huang P, Xu YZ, et al. Gemcitabine: Metabolism, mechanisms of action, and self-potentiation. Semin Oncol 1995;22:3-10.
2. Freise KJ, Martin-Jimenez T. Pharmacokinetics of gemcitabine and its primary metabolite in dogs after intravenous infusion. J Vet Pharmacol Ther 2006;29:147-152.
3. Freise KJ, Martin-Jimenez T. Pharmacokinetics of gemcitabine and its primary metabolite in dogs after intravenous bolus dosing and its in vitro pharmacodynamics. J Vet Pharmacol Ther 2006;29:137-145.
4. Mini E, Nobili S, Caciagli B, et al. Cellular pharmacology of gemcitabine. Ann Oncol 2006;17(Suppl 5):v7-v12.
5. Mose S, Class R, Weber HW, et al. Radiation enhancement by gemcitabine-mediated cell cycle modulations. Am J Clin Oncol 2003;26:60-69.
6. Rosier JF, Bruniaux M, Husson B, et al. Role of 2′-2′ difluorodeoxycytidine (gemcitabine)-induced cell cycle dysregula-
7. tion in radio-enhancement of human head and neck squamous cell carcinomas. Radiother Oncol 2004;70:55-61.
8. van Moorsel CJ, Veerman G, Bergman AM, et al. Combination chemotherapy studies with gemcitabine. Semin Oncol 1997;24:S7-17-S17-23.
9. Lawrence TS, Eisbruch A, Shewach DS. Gemcitabine-mediated radiosensitization. Semin Oncol 1997;24:S7-24-S27-28.
10. Shewach DS, Lawrence TS. Gemcitabine and radiosensitization in human tumor cells. Invest New Drugs 1996;14:257-263.
11. Kosarek CE, Kisseberth WC, Gallant SL, et al. Clinical evaluation of gemcitabine in dogs with spontaneously occurring malignancies. J Vet Intern Med 2005;19:81-86.
12. Turner AI, Hahn KA, Rusk A, et al. Single agent gemcitabine chemotherapy in dogs with spontaneously occurring lymphoma. J Vet Intern Med 2006;20:1384-1388.
13. Yarbro CH. Carboplatin: A clinical review. Semin Oncol Nurs 1989;5:63-69.
14. Wagstaff AJ, Ward A, Benfield P, et al. Carboplatin. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of cancer. Drugs 1989;37:162-190.
15. Koeller JM, Trump DL, Tutsch KD, et al. Phase I clinical trial and pharmacokinetics of carboplatin (NSC 241240) by single monthly 30-minute infusion. Cancer 1986;57:222-225.
16. Page RL, McEntee MC, George SL, et al. Pharmacokinetic and phase I evaluation of carboplatin in dogs. J Vet Intern Med 1993;7:235-240.
17. O'Brien ME, Talbot DC, Smith IE. Carboplatin in the treatment of advanced breast cancer: A phase II study using a pharmaco-kinetically guided dose schedule. J Clin Oncol 1993;11:2112-2117.
18. Egorin MJ, Jodrell DI. Utility of individualized carboplatin dosing alone and in combination regimens. Semin Oncol 1992;19:132-138.
19. Bergman PJ, MacEwen EG, Kurzman ID, et al. Amputation and carboplatin for treatment of dogs with osteosarcoma: 48 cases (1991 to 1993). J Vet Intern Med 1996;10:76-81.
20. Rassnick KM, Ruslander DM, Cotter SM, et al. Use of carboplatin for treatment of dogs with malignant melanoma: 27 cases (1989-2000). J Am Vet Med Assoc 2001;218:1444-1448.
21. Chun R, Knapp DW, Widmer WR, et al. Phase II clinical trial of carboplatin in canine transitional cell carcinoma of the urinary bladder. J Vet Intern Med 1997;11:279-283.
22. Murphy S, Hayes A, Adams V, et al. Role of carboplatin in multi-modality treatment of canine tonsillar squamous cell carcinoma-A case series of five dogs. J Small Anim Pract 2006;47:216-220.
23. Bergman AM, Ruiz van Haperen VW, Veerman G, et al. Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res 1996;2:521-530.
24. van Moorsel CJ, Pinedo HM, Veerman G, et al. Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines. Br J Cancer 1999;80:981-990.
25. Moufarij MA, Phillips DR, Cullinane C. Gemcitabine potentiates cisplatin cytotoxicity and inhibits repair of cisplatin-DNA damage in ovarian cancer cell lines. Mol Pharmacol 2003;63: 862-869.
26. Gandara DR, Lau DH, Lara Jr. PN, et al. Gemcitabine/carboplatin combination regimens: Importance of dose schedule. Oncology (Williston Park) 2000;14:26-30.
27. Peters GJ, Bergman AM, Ruiz van Haperen VW, et al. Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 1995;22:72-79.
28. Bergman AM, Ruiz van Haperen VW, Veerman G, et al. Synergistic interaction between cisplatin and gemcitabine in ovarian and colon cancer cell lines. Adv Exp Med Biol 1994;370:139-143.
29. Lorvidhaya V, Kamnerdsupaphon P, Chitapanarux I, et al. Cisplatin and gemcitabine in patients with metastatic cervical cancer. Gan To Kagaku Ryoho 2004;31:1057-1062.
30. Nasr FL, Chahine GY, Kattan JG, et al. Gemcitabine plus carboplatin combination therapy as second-line treatment in patients with relapsed breast cancer. Clin Breast Cancer 2004;5:117- 122; discussion 123-124.
31. Hoschke B, May M, Seehafer M, et al. Our experience with 23 consecutive patients on gemcitabine/carboplatin chemotherapy for treatment of metastasized transitional cell carcinoma of the urothelium. Int J Urol 2004;11:461-466.
32. Ngan RK, Yiu HH, Lau WH, et al. Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: Report of a phase II study. Ann Oncol 2002;13:1252-1258.
33. Heinemann V. Gemcitabine plus cisplatin for the treatment of metastatic breast cancer. Clin Breast Cancer 2002;3(Suppl 1): 24-29.
34. Shannon C, Crombie C, Brooks A, et al. Carboplatin and gemcitabine in metastatic transitional cell carcinoma of the urothelium: Effective treatment of patients with poor prognostic features. Ann Oncol 2001;12:947-952.
35. Moore AS, Kitchell BE. New chemotherapy agents in veterinary medicine. Vet Clin North Am Small Anim Pract 2003;33: 629-649, viii.
36. Dodion P, Kenis Y, Staquet M. Phase I trials of single agents in adult solid tumours: Preclinical and clinical aspects. Drugs Exp Clin Res 1986;12:23-30.
37. Boyce KL, Kitchell BE. Treatment of canine lymphoma with COPLA/LVP. J Am Anim Hosp Assoc 2000;36:395-403.
38. Thomas P, Robinet G, Ferri-Dessens RM, et al. Phase I trial of gemcitabine and carboplatin in metastatic non-small-cell lung cancer: A Groupe Francais de pneumo-cancerologie study. Lung Cancer 2002;36:191-198.
39. Carles J, Nogue M, Domenech M, et al. Carboplatin-gemcitabine treatment of patients with transitional cell carcinoma of the bladder and impaired renal function. Oncology 2000; 59:24-27.
40. Carmichael J, Allerheiligen S, Walling J. A phase I study of gemcitabine and carboplatin in non-small cell lung cancer. Semin Oncol 1996;23:55-59.
41. Bergh MS, Budsberg SC. The coxib NSAIDs: Potential clinical and pharmacologic importance in veterinary medicine. J Vet Intern Med 2005;19:633-643.
42. Knapp DW, Richardson RC, Bottoms GD, et al. Phase I trial of piroxicam in 62 dogs bearing naturally occurring tumors. Cancer Chemother Pharmacol 1992;29:214-218.